These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

56 related articles for article (PubMed ID: 2024232)

  • 21. Effects of antithrombin and heparin cofactor II levels on anticoagulation with Intimatan.
    Tanaka KA; Szlam F; Vinten-Johansen J; Cardin AD; Levy JH
    Thromb Haemost; 2005 Oct; 94(4):808-13. PubMed ID: 16270635
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A small fraction of dermatan sulfate with significantly increased anticoagulant activity was selected by interaction with the first complement protein.
    Calabrese GC; Alberto MF; Tubio R; Marani MM; Fernández De Recondo ME; Lazzari M; Recondo EF
    Thromb Res; 2004; 113(3-4):243-50. PubMed ID: 15140589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enoxaparin and ST elevation myocardial infarction.
    Owen A
    Eur Heart J; 2007 Dec; 28(23):2952; author reply 2952-3. PubMed ID: 17965415
    [No Abstract]   [Full Text] [Related]  

  • 24. Pharmacological properties of dermatan sulfate, of a low molecular weight dermatan sulfate and of two oversulfated derivatives.
    Dol F; Petitou M; Choay J; Sie P; Houin G; Boneu B
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1989; 116(6):851-7. PubMed ID: 2483702
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Analysis of heparin sodium by SAX/HPLC for contaminants and impurities.
    Trehy ML; Reepmeyer JC; Kolinski RE; Westenberger BJ; Buhse LF
    J Pharm Biomed Anal; 2009 Apr; 49(3):670-3. PubMed ID: 19167854
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Acute myocardial infarction: thrombolytic efficacy of 500.000 UI of streptokinase combined with heparin].
    Aninat M; Col JJ; Rankin J; Jacquet L; Anwar A; Etienne J
    Rev Med Chil; 1990 Aug; 118(8):862-7. PubMed ID: 2152229
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacology of a new low molecular weight dermatan sulphate (Desmin) in healthy volunteers: repeated daily intramuscular administration of 400 mg for a week.
    Dettori AG; Zamboni V; Manotti C; Canova N; Barbanti M; Palazzini E
    Thromb Res; 1996 Jul; 83(1):103-9. PubMed ID: 8837309
    [No Abstract]   [Full Text] [Related]  

  • 28. Heparin and antithrombotic efficacy.
    Wieslander JB
    Plast Reconstr Surg; 1997 Jul; 100(1):280-1. PubMed ID: 9207694
    [No Abstract]   [Full Text] [Related]  

  • 29. Tolerability and clinical efficacy of desmin in the treatment of superficial thrombovaricophlebitis.
    Andreozzi GM; Signorelli S; Di Pino L; Martini R; Marchitelli E; Pinto A; Romeo S; Zamboni V; Palazzini E
    Angiology; 1996 Sep; 47(9):887-94. PubMed ID: 8810655
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The use of heparin-impregnated sponges to remove dried blood clots and tissue remnants on microsurgical sutures.
    Bulam H; Sezgin B; Findikçioğlu K; Tuncer S
    Microsurgery; 2015 Jan; 35(1):81-2. PubMed ID: 25043874
    [No Abstract]   [Full Text] [Related]  

  • 31. Dermatan sulfate enhances the lysis of laser-induced thrombus in vivo.
    Krupinski K; Bielawiec M; Yoshida K; Kyogashima M; Takada Y; Takada A
    Thromb Res; 1998 Aug; 91(4):199-202. PubMed ID: 9736423
    [No Abstract]   [Full Text] [Related]  

  • 32. Expression of concern.
    J Clin Oncol; 2009 Sep; 27(27):4631. PubMed ID: 19797116
    [No Abstract]   [Full Text] [Related]  

  • 33. Management of antithrombotic agents for endoscopic procedures.
    ; Anderson MA; Ben-Menachem T; Gan SI; Appalaneni V; Banerjee S; Cash BD; Fisher L; Harrison ME; Fanelli RD; Fukami N; Ikenberry SO; Jain R; Khan K; Krinsky ML; Lichtenstein DR; Maple JT; Shen B; Strohmeyer L; Baron T; Dominitz JA
    Gastrointest Endosc; 2009 Dec; 70(6):1060-70. PubMed ID: 19889407
    [No Abstract]   [Full Text] [Related]  

  • 34. Chemistry of beta-heparin (chondroitinsulfuric acid-B).
    CIFONELLI JA; LUDOWIEG J; DORFMAN A
    J Biol Chem; 1958 Sep; 233(3):541-5. PubMed ID: 13575409
    [No Abstract]   [Full Text] [Related]  

  • 35. Antithrombotic agents: rationale and future directions.
    Salzman EW
    J Vasc Surg; 1991 May; 13(5):761. PubMed ID: 2027232
    [No Abstract]   [Full Text] [Related]  

  • 36. Acute and chronic effects of a new low molecular weight dermatan sulphate (Desmin 370) on blood coagulation and fibrinolysis in healthy subjects.
    Legnani C; Palareti G; Biagi R; Ludovici S; Maggiore L; Milani MR; Coccheri S
    Eur J Clin Pharmacol; 1994; 47(3):247-52. PubMed ID: 7867677
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antithrombotic effects of the association standard heparin-dermatan sulfate.
    Caranobe C; Gabaig AM; Sié P; Boneu B
    Thromb Haemost; 1991 Jan; 65(1):107. PubMed ID: 2024232
    [No Abstract]   [Full Text] [Related]  

  • 38. Standard heparin enhances the antithrombotic activity of dermatan sulfate in the rabbit but CY 216 does not.
    Cadroy Y; Dol F; Caranobe C; Petitou M; Lormeau JC; Sié P; Choay J; Boneu B
    Thromb Haemost; 1988 Apr; 59(2):295-8. PubMed ID: 2838927
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A rationale for targeting antithrombotic therapy at the vessel wall: improved antithrombotic effect and decreased risk of bleeding.
    Buchanan MR; Brister SJ
    Wien Klin Wochenschr; 1999 Feb; 111(3):81-9. PubMed ID: 10093889
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A survey of the clinical experience with dermatan sulfate.
    Gianese F; Lucchelli PE
    Semin Thromb Hemost; 1991; 17 Suppl 2():199-204. PubMed ID: 1948090
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.